These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7358963)

  • 1. Protection by a polyvalent influenza vaccine and persistence of homologous and heterologous HI antibodies during a period of two epidemic seasons.
    Pyhälä R
    J Hyg (Lond); 1980 Apr; 84(2):237-45. PubMed ID: 7358963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of influenza serum antibodies in humans following immunization with a bivalent A/Victoria and A/New Jersey vaccine.
    Boucher DW; Contreras G; Furesz J
    Can Med Assoc J; 1979 Apr; 120(7):799-802, 831. PubMed ID: 427686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.
    Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M
    JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.
    Masurel N; Laufer J
    J Hyg (Lond); 1984 Jun; 92(3):263-76. PubMed ID: 6736638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity.
    Clark A; Potter CW; Jennings R; Nicholl JP; Langrick AF; Schild GC; Wood JM; Tyrrell DA
    J Hyg (Lond); 1983 Jun; 90(3):361-70. PubMed ID: 6863910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness.
    Hirota Y; Kaji M; Ide S; Kajiwara J; Kataoka K; Goto S; Oka T
    Vaccine; 1997 Jun; 15(9):962-7. PubMed ID: 9261942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination-induced HI antibody response to intraepidemic influenza A(H3N2) virus variants of the 1996-1997 epidemic season.
    Pyhälä R; Ikonen N; Santanen R; Haanpää M; Visakorpi R; Jäppinen P; Valle M
    J Med Virol; 2001 Nov; 65(3):584-9. PubMed ID: 11596097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An attenuated influenza virus vaccine: protection against homologous and heterologous strains of virus.
    Khakoo R; Ganguly R; Waldman R
    Dev Biol Stand; 1977 Jun 1-3; 39():141-8. PubMed ID: 342305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response.
    Zuckerman MA; Wood J; Chakraverty P; Taylor J; Heath AB; Oxford JS
    J Med Virol; 1991 Feb; 33(2):133-7. PubMed ID: 2051142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the protective efficacies of the live vaccine RIT 4025 and an inactivated vaccine against a natural heterologous A/Victoria/3/75 infection.
    Delem A; Van Rensburg W; Flaskett I
    J Hyg (Lond); 1979 Oct; 83(2):221-9. PubMed ID: 385764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R
    Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
    Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
    Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
    Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
    Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Seroconversion after vaccine with trivalent influenza vaccine during the epidemic season 1990/1 in Poland].
    Brydak L; Rudnicka H; Gut W; Magdzik W; Kańtoch M
    Przegl Epidemiol; 1992; 46(3):221-9. PubMed ID: 1296247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
    de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD
    J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.
    Luytjes W; Enouf V; Schipper M; Gijzen K; Liu WM; van der Lubben M; Meijer A; van der Werf S; Soethout EC
    Vaccine; 2012 Jul; 30(35):5262-9. PubMed ID: 22691431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.